"Our previous research had shown that 84 per cent of pancreatic cancer patients have high levels of 'v '6 on their cancers." "So we are hopeful that, if we can develop this into an effective treatment for pancreatic cancer, it would have limited side effects." His team, supported by the Pancreatic Cancer Research Fund, are working with Spirogen, now part of AstraZeneca, and ADC Therapeutics. They now plan to further test the treatment in more complex mice models, to see if it can stop the spread of pancreatic cancer. There are few treatment options for pancreatic cancer patients and the cancer will become resistant to chemotherapy.

Source: Daily Mirror February 12, 2020 00:00 UTC